anonymous
Guest
anonymous
Guest
Other options commercialized by more credible and established companies are exactly why we are not seeing more traction.This past week was the worst. Was visiting a kol per call plan. he mentioned that he had reached out to Flemming about his dissatisfaction with how things are operating. He told me there’s a lot of options out there including the new Lilly drug and while he medically likes the drug he won’t be prescribing because it’s too much hassle and we lack the maturity as a company in the space. I am overall not seeing the prescriptions in mine or others terrs